The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Ben McCullough met the 25 Edwards Lifesciences technicians who spent 20 hours hand-sewing 2,000 stitches to make a valve ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

A EUROPEAN post-market registry study has demonstrated that tricuspid transcatheter edge-to-edge repair (T-TEER) using the ...

The chordae tendineae (CT), often referred to as the “heart strings,” are thin, tendinous structures that connect the heart ...

Abbott Laboratories ABT recently unveiled favorable TRILUMINATE Pivotal trial data at the American College of Cardiology's Annual Scientific Session (ACC.25), held in Chicago. The data demonstrated ...